PE20080188A1 - Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol - Google Patents
Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterolInfo
- Publication number
- PE20080188A1 PE20080188A1 PE2007000463A PE2007000463A PE20080188A1 PE 20080188 A1 PE20080188 A1 PE 20080188A1 PE 2007000463 A PE2007000463 A PE 2007000463A PE 2007000463 A PE2007000463 A PE 2007000463A PE 20080188 A1 PE20080188 A1 PE 20080188A1
- Authority
- PE
- Peru
- Prior art keywords
- reduce
- ppar
- acetic acid
- benzoazepine
- oxy
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- XWRCWBNSNDDBQB-UHFFFAOYSA-N 2-(1h-1-benzazepin-2-yloxy)acetic acid Chemical class N1C(OCC(=O)O)=CC=CC2=CC=CC=C21 XWRCWBNSNDDBQB-UHFFFAOYSA-N 0.000 title 1
- 108010023302 HDL Cholesterol Proteins 0.000 title 1
- 108010028554 LDL Cholesterol Proteins 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 4-TRIFLUOROMETHYL-PHENYL Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- SKMUADUXCABNRO-UHFFFAOYSA-N 3-methyl-2h-1,3-thiazole Chemical group CN1CSC=C1 SKMUADUXCABNRO-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229930192474 thiophene Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/16—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE X ES UN ENLACE COVALENTE, O, S; R1 y R2 SON CADA UNO H, ALQUILO C1-C8 SUSTITUIDO O NO O FORMAN JUNTO AL ATOMO DE CARBONO CICLOALQUILO C3-C7; R3 ES H; R4 y R5 SON CADA UNO H, HALO, ALQUILO C1-C8, ENTRE OTROS; R6 y R7 SON CADA UNO H, HALO, ALQUILO C1-C3, ALCOXI C1-C3, ENTRE OTROS; n ES 1; Q ES 1,2-TIAZOL, TIAZOL, TIOFENO, 3-METILTIAZOL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO {3-[3-(4-TRIFLUOROMETIL-FENIL)ISOTIAZOL-5-ILMETIL]-2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-ILOXI)-ACETICO; ACIDO 2-METIL-2-{3-[3-(4-TRIFLUOROMETIL-FENIL)-ISOTIAZOL-5-ILMETIL} 2,3,4,5-TETRAHIDRO-1H-BENZO[d]AZEPIN-7-ILOXI}-PROPIONICO; ENTRE OTROS. SE REFIERE TAMBIEN UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON AGONISTAS DE RECEPTORES ACTIVADOS POR EL PROLIFERADOR DE PEROXISOMA (PPAR), UTILES EN EL TRATAMIENTO DE NEUROPATIA, RETINOPATIA, NEFROPATIA, CATARATAS, ATEROSCLEROSIS Y OTROS TRASTORNOS RELACIONADOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79300106P | 2006-04-18 | 2006-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080188A1 true PE20080188A1 (es) | 2008-03-10 |
Family
ID=38610435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000463A PE20080188A1 (es) | 2006-04-18 | 2007-04-16 | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US7678786B2 (es) |
| EP (1) | EP2010289B1 (es) |
| JP (1) | JP5232771B2 (es) |
| KR (1) | KR101472370B1 (es) |
| CN (1) | CN101479008B (es) |
| AR (1) | AR060489A1 (es) |
| AT (1) | ATE535282T1 (es) |
| AU (1) | AU2007237928B2 (es) |
| BR (1) | BRPI0711695A2 (es) |
| CA (1) | CA2649700C (es) |
| CO (1) | CO6160296A2 (es) |
| CR (1) | CR10447A (es) |
| EA (1) | EA016583B1 (es) |
| EC (1) | ECSP088841A (es) |
| ES (1) | ES2375754T3 (es) |
| GT (1) | GT200800226A (es) |
| HK (1) | HK1124797A1 (es) |
| HN (1) | HN2008001559A (es) |
| IL (1) | IL194850A (es) |
| JO (1) | JO3444B1 (es) |
| MX (1) | MX2008013534A (es) |
| MY (1) | MY144637A (es) |
| NO (1) | NO344334B1 (es) |
| NZ (1) | NZ571998A (es) |
| PE (1) | PE20080188A1 (es) |
| TW (1) | TWI404712B (es) |
| UA (1) | UA96150C2 (es) |
| UY (1) | UY30288A1 (es) |
| WO (1) | WO2007121432A2 (es) |
| ZA (1) | ZA200809790B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8771643B2 (en) * | 2008-01-04 | 2014-07-08 | Schabar Research Associates Llc | Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2725680A1 (en) | 2008-05-30 | 2009-12-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2563770B1 (en) | 2010-04-28 | 2016-03-23 | Leo Pharma A/S | Biaryl phosphodiesterase inhibitors |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012007500A2 (de) | 2010-07-15 | 2012-01-19 | Bayer Cropscience Ag | Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| US20130197043A1 (en) | 2010-08-31 | 2013-08-01 | Snu R&Db Foundation | Use of the fetal reprogramming of a ppar agonist |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013124382A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for use in the treatment of cardiovascular disorders |
| WO2013124380A1 (en) | 2012-02-24 | 2013-08-29 | Nestec S.A. | Peltatin for the treatment of chronic inflammatory disorders |
| EP2817006A1 (en) | 2012-02-24 | 2014-12-31 | Nestec S.A. | Peltatin for use in the treatment of metabolic disorders |
| US9695137B2 (en) * | 2013-03-14 | 2017-07-04 | The University Of Toledo | Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same |
| WO2016057322A1 (en) * | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US20210145775A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| AU2021310264A1 (en) | 2020-07-15 | 2023-02-09 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn |
| CA3124579A1 (en) | 2020-07-15 | 2022-01-15 | Schabar Research Associates Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2460689C3 (de) * | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US4125732A (en) * | 1977-05-06 | 1978-11-14 | American Cyanamid Company | 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters |
| DE3026924A1 (de) | 1980-07-16 | 1982-02-18 | Klinge Pharma GmbH & Co, 8000 München | 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| DE3028776A1 (de) | 1980-07-29 | 1982-02-25 | Klinge Pharma GmbH & Co, 8000 München | Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| DE3169761D1 (en) | 1981-01-09 | 1985-05-09 | Fisons Plc | Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them |
| JPS58177934A (ja) | 1982-04-13 | 1983-10-18 | Takeda Chem Ind Ltd | ベンゾキノン誘導体 |
| DE3366107D1 (en) | 1982-09-30 | 1986-10-16 | Merck Frosst Canada Inc | Leukotriene antagonists, their production, and compositions containing them |
| US4820867A (en) | 1983-04-21 | 1989-04-11 | Merck Frosst Canada, Inc. | Phenoxypropoxy halophenylacetic acids as leukotriene antagonists |
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| JPS61268651A (ja) | 1985-05-23 | 1986-11-28 | Takeda Chem Ind Ltd | フエニル酢酸誘導体およびその製造法 |
| EP0204349A3 (de) | 1985-06-01 | 1990-01-03 | Dr. Karl Thomae GmbH | Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH0714910B2 (ja) | 1988-12-13 | 1995-02-22 | 塩野義製薬株式会社 | 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤 |
| US5487008A (en) * | 1990-04-20 | 1996-01-23 | The Regents Of The University Of Michigan | Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain |
| CA2092152A1 (en) * | 1992-03-23 | 1993-09-24 | Azuma Igarashi | Phenoxyacetic acid compounds and medical preparations containing them |
| US5726165A (en) * | 1994-07-29 | 1998-03-10 | Smithkline Beecham P.L.C. | Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor |
| WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
| AU712607B2 (en) | 1996-02-02 | 1999-11-11 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| JP3268242B2 (ja) | 1996-11-14 | 2002-03-25 | 三共株式会社 | 縮合複素環化合物を含有する医薬 |
| DE69840510D1 (de) | 1997-07-24 | 2009-03-12 | Astellas Pharma Inc | Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| MXPA03011201A (es) | 2001-06-07 | 2004-02-26 | Lilly Co Eli | Moduladores de receptores activados por proliferadores de persoxisomas. |
| BR0211414A (pt) | 2001-07-30 | 2004-08-17 | Novo Nordisk As | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas |
| PT1424330E (pt) * | 2001-08-10 | 2011-12-22 | Nippon Chemiphar Co | Activador do receptor ä responsivo a proliferadores peroxissomais |
| EA200400140A1 (ru) * | 2001-08-29 | 2004-08-26 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си | Пероральные противодиабетические агенты |
| EP1445258B1 (en) | 2001-10-12 | 2009-06-24 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor delta |
| ITRM20020014A1 (it) | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
| WO2003074495A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Hppars activators |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| MXPA05002411A (es) | 2002-09-05 | 2005-05-27 | Novo Nordisk As | Nuevos derivados de acido vinil carboxilico y su uso terapeutico. |
| AU2003273784A1 (en) | 2002-10-28 | 2004-05-13 | Novo Nordisk A/S | Novel compounds useful in treating ppar mediated diseases |
| AU2003273783C1 (en) | 2002-10-28 | 2010-08-12 | Vtv Therapeutics Llc | Novel compounds and their use as PPAR-modulators |
| EP1581521A1 (en) * | 2003-01-06 | 2005-10-05 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| WO2004063155A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
| CA2515481A1 (en) | 2003-02-14 | 2004-09-02 | Biogen Idec Ma Inc. | An expression cassette and vector for transient or stable expression of exogenous molecules |
| PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
| US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| US6987118B2 (en) * | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| WO2005019151A1 (en) * | 2003-08-20 | 2005-03-03 | Eli Lilly And Company | Ppar modulators |
| SI2243766T1 (sl) * | 2003-09-19 | 2015-12-31 | Janssen Pharmaceutica N.V. | 4-((fenoksialkil)tio)-fenoksiocetne kisline za uporabo pri zdravljenju stanj, ki jih posreduje ppar-delta |
| EP1667964B1 (en) | 2003-09-19 | 2009-07-22 | Janssen Pharmaceutica N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| AU2004285530A1 (en) | 2003-10-31 | 2005-05-12 | Janssen Pharmaceutica N.V. | Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (PPAR) dual agonists |
| WO2005060958A1 (en) * | 2003-12-19 | 2005-07-07 | Kalypsys, Inc. | (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes |
| PE20060185A1 (es) | 2004-04-21 | 2006-03-20 | Schering Corp | ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA |
| WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
| BRPI0512951A (pt) * | 2004-07-01 | 2008-04-15 | Hoffmann La Roche | compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha) |
| CN101018790A (zh) * | 2004-09-11 | 2007-08-15 | 塞诺菲-安万特德国有限公司 | 7－氮杂吲哚以及其用作ppar激动剂的应用 |
| PE20060664A1 (es) | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| MY145712A (en) * | 2004-09-15 | 2012-03-30 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| MY147518A (en) | 2004-09-15 | 2012-12-31 | Janssen Pharmaceutica Nv | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| JO3006B1 (ar) | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| AU2007210076A1 (en) * | 2006-01-30 | 2007-08-09 | Irm Llc | Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as PPAR modulators |
| GB0618963D0 (en) * | 2006-09-26 | 2006-11-08 | Ucl Business Plc | Formulations and composites with reactive fillers |
-
2007
- 2007-04-16 PE PE2007000463A patent/PE20080188A1/es active IP Right Grant
- 2007-04-16 UY UY30288A patent/UY30288A1/es active IP Right Grant
- 2007-04-17 WO PCT/US2007/066772 patent/WO2007121432A2/en active Application Filing
- 2007-04-17 AT AT07760766T patent/ATE535282T1/de active
- 2007-04-17 CN CN2007800226398A patent/CN101479008B/zh not_active Expired - Fee Related
- 2007-04-17 AR ARP070101628A patent/AR060489A1/es active IP Right Grant
- 2007-04-17 TW TW096113405A patent/TWI404712B/zh not_active IP Right Cessation
- 2007-04-17 MY MYPI20084161A patent/MY144637A/en unknown
- 2007-04-17 JP JP2009506716A patent/JP5232771B2/ja not_active Expired - Fee Related
- 2007-04-17 AU AU2007237928A patent/AU2007237928B2/en not_active Ceased
- 2007-04-17 MX MX2008013534A patent/MX2008013534A/es active IP Right Grant
- 2007-04-17 CA CA2649700A patent/CA2649700C/en not_active Expired - Fee Related
- 2007-04-17 BR BRPI0711695-0A patent/BRPI0711695A2/pt not_active IP Right Cessation
- 2007-04-17 EA EA200870445A patent/EA016583B1/ru unknown
- 2007-04-17 JO JOP/2007/0139A patent/JO3444B1/ar active
- 2007-04-17 US US11/736,221 patent/US7678786B2/en active Active
- 2007-04-17 UA UAA200813306A patent/UA96150C2/ru unknown
- 2007-04-17 NZ NZ571998A patent/NZ571998A/en not_active IP Right Cessation
- 2007-04-17 EP EP07760766A patent/EP2010289B1/en active Active
- 2007-04-17 ES ES07760766T patent/ES2375754T3/es active Active
-
2008
- 2008-10-17 HN HN2008001559A patent/HN2008001559A/es unknown
- 2008-10-21 GT GT200800226A patent/GT200800226A/es unknown
- 2008-10-22 EC EC2008008841A patent/ECSP088841A/es unknown
- 2008-10-22 IL IL194850A patent/IL194850A/en active IP Right Grant
- 2008-10-24 CO CO08113909A patent/CO6160296A2/es unknown
- 2008-11-14 KR KR1020087027903A patent/KR101472370B1/ko not_active Expired - Fee Related
- 2008-11-17 ZA ZA2008/09790A patent/ZA200809790B/en unknown
- 2008-11-18 CR CR10447A patent/CR10447A/es unknown
- 2008-11-18 NO NO20084847A patent/NO344334B1/no not_active IP Right Cessation
-
2009
- 2009-03-09 HK HK09102249.6A patent/HK1124797A1/xx not_active IP Right Cessation
-
2010
- 2010-01-19 US US12/689,335 patent/US8633184B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080188A1 (es) | Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol | |
| PE20091901A1 (es) | Activadores de glucoquinasa | |
| PE20081263A1 (es) | DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| PE20021152A1 (es) | Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
| PE20050417A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparacion | |
| PE20081404A1 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion | |
| PE20121522A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
| PE20080065A1 (es) | Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1 | |
| PE20091222A1 (es) | Bifenilo sustituidos como moduladores del receptor gpra40 | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| ES2572148T3 (es) | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados | |
| PE20081475A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| PE20120764A1 (es) | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20121280A1 (es) | Derivados de (tio)morfolina como moduladores de s1p | |
| PE20091102A1 (es) | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 | |
| PE20040987A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
| PE20090892A1 (es) | MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3 | |
| NZ629630A (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |